Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Number: NCT00579514 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
Number: NCT00588185 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
Number: NCT01985828 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s): |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Number: NCT02465060 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can
Number: NCT02484404 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s): |
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Number: NCT02946996 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Medical University of South Carolina Sponsor Trial Information Trial Location(s) and Contact(s): |
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Number: NCT02949284 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rutgers, The State University of New Jersey|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Number: NCT02960022 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Astellas Pharma Global Development, Inc.|Pfizer|Astellas Pharma Inc Sponsor Trial Information Trial Location(s) and Contact(s): |
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Number: NCT03016741 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Northwestern University Sponsor Trial Information Trial Location(s) and Contact(s): |
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Number: NCT03047135 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s): |
Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer
Number: NCT03085043 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Number: NCT03333616 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana-Farber Cancer Institute|Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s): |
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Number: NCT03419234 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s): |
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Number: NCT03436654 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s): |
Ultra-hypofractionated Radiation in Prostate Cancer
Number: NCT03486821 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
Number: NCT03541928 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The Methodist Hospital Research Institute Sponsor Trial Information Trial Location(s) and Contact(s): |
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Number: NCT03582475 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s): |
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
Number: NCT03624660 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
Number: NCT03637543 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Beth Israel Deaconess Medical Center|Bristol-Myers Squibb|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s): |
Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer
Number: NCT03654638 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation
Number: NCT03657108 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Number: NCT03678025 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Southwest Oncology Group|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer
Number: NCT03697148 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Number: NCT03753243 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Mark Garzotto, MD|Merck Sharp & Dohme LLC|Astellas Pharma Inc|Portland VA Medical Center Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Number: NCT03767244 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s): |
Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Number: NCT03777982 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Dana-Farber Cancer Institute|Janssen Scientific Affairs, LLC Sponsor Trial Information Trial Location(s) and Contact(s): |
The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer
Number: NCT03808077 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
Number: NCT03821792 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland|California Walnut Commission|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
Number: NCT03833921 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Martha Mims|Baylor College of Medicine Sponsor Trial Information Trial Location(s) and Contact(s): |
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
Number: NCT03860987 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s): |
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
Number: NCT03880422 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Number: NCT03899987 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Roswell Park Cancer Institute|AIM ImmunoTech Inc. Sponsor Trial Information Trial Location(s) and Contact(s): |
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
Number: NCT03910660 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): BioXcel Therapeutics Inc Sponsor Trial Information Trial Location(s) and Contact(s): |
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
Number: NCT03976843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s): |
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
Number: NCT03987386 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
Number: NCT04011410 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew C. James, MD|University of Kentucky Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
Number: NCT04019327 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
Number: NCT04030559 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, Davis|National Cancer Institute (NCI)|Janssen, LP Sponsor Trial Information Trial Location(s) and Contact(s): |
RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
Number: NCT04037358 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s): |
OPTimizing Treatment Focused Genetic Testing IN Cancer
Number: NCT04066361 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Number: NCT04126070 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Xiao X. Wei|Bristol-Myers Squibb|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s): |
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
Number: NCT04134260 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
Number: NCT04136353 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Bayer|Cancer Trials Ireland|Canadian Cancer Trials Group|Memorial Sloan Kettering Cancer Center|Prostate Cancer Clinical Trials Consortium Sponsor Trial Information Trial Location(s) and Contact(s): |
The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
Number: NCT04167969 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Memorial Sloan Kettering Cancer Center|Elucida Oncology|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
Number: NCT04179968 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana Mathews|University of Texas Southwestern Medical Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Serial MRI Scans During Radiation Therapy
Number: NCT04188535 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
Number: NCT04194554 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): University of Michigan Rogel Cancer Center|Janssen Scientific Affairs, LLC Sponsor Trial Information Trial Location(s) and Contact(s): |
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
Number: NCT04246671 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Bavarian Nordic Sponsor Trial Information Trial Location(s) and Contact(s): |
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
Number: NCT04253483 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rutgers, The State University of New Jersey|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Number: NCT04262154 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center|Genentech, Inc. Sponsor Trial Information Trial Location(s) and Contact(s): |
AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
Number: NCT04263025 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2|Phase 3 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
Number: NCT04267887 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): OHSU Knight Cancer Institute|Janssen Scientific Affairs, LLC|Oregon Health and Science University Sponsor Trial Information Trial Location(s) and Contact(s): |
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
Number: NCT04301414 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Matthew Dallos|Bristol-Myers Squibb|Ferring Pharmaceuticals|Columbia University Sponsor Trial Information Trial Location(s) and Contact(s): |
Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer
Number: NCT04346225 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rahul Aggarwal|National Cancer Institute (NCI)|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s): |
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s): |
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Number: NCT04383210 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Elevation Oncology Sponsor Trial Information Trial Location(s) and Contact(s): |
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer
Number: NCT04390880 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Greater Los Angeles Healthcare System Sponsor Trial Information Trial Location(s) and Contact(s): |
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
Number: NCT04396808 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
Number: NCT04402151 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors
Number: NCT04423029 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s): |
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
Number: NCT04465500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Virginia Sponsor Trial Information Trial Location(s) and Contact(s): |
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
Number: NCT04493853 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s): |
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Number: NCT04513717 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
Number: NCT04530552 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Number: NCT04550494 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
Number: NCT04552509 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
Number: NCT04600336 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Number: NCT04606446 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s): |
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Number: NCT04644068 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s): |
Brain and Pelvic Floor Muscle Activity of Patients Undergoing Robot-Assisted Radical Prostatectomy
Number: NCT04646434 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Number: NCT04666129 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Myovant Sciences GmbH Sponsor Trial Information Trial Location(s) and Contact(s): |
Single-Port Versus Multi-Port Robotic Radical Prostatectomy
Number: NCT04696263 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
Number: NCT04700332 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Hoag Memorial Hospital Presbyterian Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
Number: NCT04709276 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew J. Armstrong, MD|Bristol-Myers Squibb|Duke University Sponsor Trial Information Trial Location(s) and Contact(s): |
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
Number: NCT04725903 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Emory University|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Number: NCT04734730 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s): |
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer
Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s): |
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study
Number: NCT04870515 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Number: NCT04898634 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s): |
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy
Number: NCT04905069 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
Number: NCT04945642 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
Number: NCT04947254 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer
Number: NCT04981834 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Insulin Resistance and Androgen Deprivation Therapy
Number: NCT04995978 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): St. Louis University Sponsor Trial Information Trial Location(s) and Contact(s): |
COAST Therapy in Advanced Solid Tumors and Prostate Cancer
Number: NCT05036226 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Medical University of South Carolina Sponsor Trial Information Trial Location(s) and Contact(s): |
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
Number: NCT05038332 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Michigan Rogel Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
Number: NCT05043012 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer
Number: NCT05055843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Massage for Prostate Cancer-Related Fatigue, mPROSTATE Study
Number: NCT05067777 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Pioglitazone and Insulin Resistance in ADT
Number: NCT05098327 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): State University of New York at Buffalo Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
Number: NCT05100472 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
Number: NCT05133440 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Number: NCT05219500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Excel Diagnostics and Nuclear Oncology Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer
Number: NCT05224869 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Icahn School of Medicine at Mount Sinai Sponsor Trial Information Trial Location(s) and Contact(s): |
T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
Number: NCT05361798 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
Number: NCT05375539 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
PSMA-PET to Guide Prostatectomy
Number: NCT05381103 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2|Phase 3 Sponsor(s): Five Eleven Pharma, Inc.|Indiana University Sponsor Trial Information Trial Location(s) and Contact(s): |
Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
Number: NCT05384535 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
Number: NCT05477823 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |